Denali Therapeutics Inc. Common Stock
DNLINASDAQHealthcare · Biological Products, (no Diagnostic Substances)
Market cap
$3.21B
Employees
507
Exchange
NASDAQ
Headquarters
SOUTH SAN FRANCISCO, CA
About Denali Therapeutics Inc. Common Stock
Denali Therapeutics Inc is a biotechnology company that is engaged in developing and discovering therapeutics to defeat neurodegenerative diseases. The company's development programs include the LRRK2 Inhibitor Program, which develops brain penetrant small molecule LRRK2 inhibitor product candidates for Parkinson's disease. Its key products include DNL201, DNL151, ATV (Antibody Transport Vehicle), ETV (Enzyme Transport Vehicle), and others. The Company has one operating segment with the goal to discover, develop, and commercializing therapeutics.
Industry
Biological Products, (no Diagnostic Substances)
Sector
Healthcare
Country
US
Website
www.denalitherapeutics.com